Keele Research Repository
Explore the Repository
Article
Oswald, AJ, Symeonides, SN, Wheatley, D, Chan, S, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Chisholm, EM, Welsh, M, Hill, R, Hopcroft, LEM, Barrett-Lee, P and Cameron, DA (2023) Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment.
Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.